Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
OtherArticle

Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor

Xushan Wang, Erik J Hembre, Paul J Goldsmith, James P Beck, Kjell A Svensson, Francis S. Willard and Robert F Bruns
Molecular Pharmacology December 12, 2022, MOLPHARM-AR-2022-000605; DOI: https://doi.org/10.1124/molpharm.122.000605
Xushan Wang
1Molecular Pharmacology, Lilly Research Laboratories, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik J Hembre
2DCRT, Eli Lilly and Company, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J Goldsmith
3Lilly Research Center, Lilly Research Laboratories, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James P Beck
4Discovery Chemistry Research and Technologies, Lilly Research Laboratories, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kjell A Svensson
5Neuroscience, Eli Lilly and Company, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis S. Willard
1Molecular Pharmacology, Lilly Research Laboratories, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francis S. Willard
  • For correspondence: willardfs@lilly.com
Robert F Bruns
6retired, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert F Bruns
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

MOLPHARM-AR-2022-000605
DOI 
https://doi.org/10.1124/molpharm.122.000605

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Published online December 12, 2022.

Copyright & Usage 
© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution CC BY License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Author Information

  1. Xushan Wang1,
  2. Erik J Hembre2,
  3. Paul J Goldsmith3,
  4. James P Beck4,
  5. Kjell A Svensson5,
  6. Francis S. Willard1,*, and
  7. Robert F Bruns6
  1. 1Molecular Pharmacology, Lilly Research Laboratories, United States
  2. 2DCRT, Eli Lilly and Company, United States
  3. 3Lilly Research Center, Lilly Research Laboratories, United Kingdom
  4. 4Discovery Chemistry Research and Technologies, Lilly Research Laboratories, United States
  5. 5Neuroscience, Eli Lilly and Company, United States
  6. 6retired, United States
  1. ↵* Corresponding Author:
    Francis S. Willard, Molecular Pharmacology, Lilly Research Laboratories, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, 46285, United States. E-mail: willardfs{at}lilly.com

Statistics from Altmetric.com

Article usage

Article usage: December 2022 to February 2023

AbstractFullPdf
Dec 2022241078
Jan 2023240060
Feb 2023502

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 103 (2)
Molecular Pharmacology
Vol. 103, Issue 2
1 Feb 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Three Allosteric Sites on the Dopamine D1 Receptor

Xushan Wang, Erik J Hembre, Paul J Goldsmith, James P Beck, Kjell A Svensson, Francis S. Willard and Robert F Bruns
Molecular Pharmacology December 12, 2022, MOLPHARM-AR-2022-000605; DOI: https://doi.org/10.1124/molpharm.122.000605

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Three Allosteric Sites on the Dopamine D1 Receptor

Xushan Wang, Erik J Hembre, Paul J Goldsmith, James P Beck, Kjell A Svensson, Francis S. Willard and Robert F Bruns
Molecular Pharmacology December 12, 2022, MOLPHARM-AR-2022-000605; DOI: https://doi.org/10.1124/molpharm.122.000605
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics